share_log

eFFECTOR Therapeutics | 424B5: Prospectus

eFFECTOR Therapeutics | 424B5: Prospectus

eFFECTOR Therapeutics | 424B5：募资说明书
美股sec公告 ·  04/04 08:20
Moomoo AI 已提取核心信息
eFFECTOR Therapeutics, listed on the Nasdaq Capital Market under the symbol EFTR, has filed a prospectus supplement on April 4, 2024, to amend and supplement its previous prospectus dated September 9, 2022. The company has reported the sale of 640,305 shares of common stock, raising gross proceeds of approximately $8.5 million under a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. The current prospectus supplement allows for the offering and sale of additional shares with an aggregate offering price of up to $6,762,420. This offering is subject to the limitations of General Instruction I.B.6 of Form S-3, which restricts the amount eFFECTOR Therapeutics may sell. The company's public float as of April 1, 2024, was valued at $69.0 million, based on a closing stock price of $16.95 per share on March 4, 2024. Over the past 12 months, eFFECTOR Therapeutics has sold $16,235,001 worth of securities. The company cautions that investing in its common stock carries a high degree of risk, as detailed in the 'Risk Factors' section of the Prospectus.
eFFECTOR Therapeutics, listed on the Nasdaq Capital Market under the symbol EFTR, has filed a prospectus supplement on April 4, 2024, to amend and supplement its previous prospectus dated September 9, 2022. The company has reported the sale of 640,305 shares of common stock, raising gross proceeds of approximately $8.5 million under a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. The current prospectus supplement allows for the offering and sale of additional shares with an aggregate offering price of up to $6,762,420. This offering is subject to the limitations of General Instruction I.B.6 of Form S-3, which restricts the amount eFFECTOR Therapeutics may sell. The company's public float as of April 1, 2024, was valued at $69.0 million, based on a closing stock price of $16.95 per share on March 4, 2024. Over the past 12 months, eFFECTOR Therapeutics has sold $16,235,001 worth of securities. The company cautions that investing in its common stock carries a high degree of risk, as detailed in the 'Risk Factors' section of the Prospectus.
Effector Therapeutics在纳斯达克资本市场上市，股票代码为EFTR，已于2024年4月4日提交了招股说明书补充文件，以修改和补充其先前于2022年9月9日发布的招股说明书。该公司报告称，根据与坎托·菲茨杰拉德公司签订的受控股权发行销售协议，出售了640,305股普通股，筹集了约850万美元的总收益。当前的招股说明书补充文件允许发行和出售额外股票，总发行价最高为6,762,420美元。本次发行受S-3表格I.B.6通用说明的限制，该说明限制了Effector Therapeutics可以出售的金额。根据2024年3月4日每股16.95美元的收盘价，截至2024年4月1日，该公司的公众持股量为6,900万美元。在过去的12个月中，Effector Therapeutics已出售了价值16,235,001美元的证券。该公司警告说，正如招股说明书的 “风险因素” 部分所详述的那样，投资普通股会带来很高的风险。
Effector Therapeutics在纳斯达克资本市场上市，股票代码为EFTR，已于2024年4月4日提交了招股说明书补充文件，以修改和补充其先前于2022年9月9日发布的招股说明书。该公司报告称，根据与坎托·菲茨杰拉德公司签订的受控股权发行销售协议，出售了640,305股普通股，筹集了约850万美元的总收益。当前的招股说明书补充文件允许发行和出售额外股票，总发行价最高为6,762,420美元。本次发行受S-3表格I.B.6通用说明的限制，该说明限制了Effector Therapeutics可以出售的金额。根据2024年3月4日每股16.95美元的收盘价，截至2024年4月1日，该公司的公众持股量为6,900万美元。在过去的12个月中，Effector Therapeutics已出售了价值16,235,001美元的证券。该公司警告说，正如招股说明书的 “风险因素” 部分所详述的那样，投资普通股会带来很高的风险。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息